Ibrutinib, the first in class of BTK inhibitor, has improved the management of patients with chronic lymphocytic leukemia. Since ibrutinib can cause atrial fibrillation in 6-16% of cases, it is clinically relevant to identify patients at higher risk to develop atrial fibrillation. Comorbidities associated with a higher risk to develop atrial fibrillation were recapitulated in a scoring system. This model proved to be a valid prognostic tool both in a general chronic lymphocytic leukemia population (n=860) and in an ibrutinib-treated cohort (n=354). Patients with score≥5 harbored the highest risk of atrial fibrillation and should be carefully monitored during ibrutinib therapy.
A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA
Visentin, A;Piazza, F;Semenzato, G;Trentin, L
2019
Abstract
Ibrutinib, the first in class of BTK inhibitor, has improved the management of patients with chronic lymphocytic leukemia. Since ibrutinib can cause atrial fibrillation in 6-16% of cases, it is clinically relevant to identify patients at higher risk to develop atrial fibrillation. Comorbidities associated with a higher risk to develop atrial fibrillation were recapitulated in a scoring system. This model proved to be a valid prognostic tool both in a general chronic lymphocytic leukemia population (n=860) and in an ibrutinib-treated cohort (n=354). Patients with score≥5 harbored the highest risk of atrial fibrillation and should be carefully monitored during ibrutinib therapy.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
